News coverage about Zafgen (NASDAQ:ZFGN) has been trending somewhat positive recently, according to Accern. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Zafgen earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 46.265620850594 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Zafgen (ZFGN) opened at $3.94 on Friday. Zafgen has a 1-year low of $3.11 and a 1-year high of $5.46.

Zafgen (NASDAQ:ZFGN) last posted its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.46) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.58) by $0.12. equities analysts forecast that Zafgen will post -2.02 earnings per share for the current fiscal year.

Several research analysts recently commented on the stock. ValuEngine upgraded shares of Zafgen from a “strong sell” rating to a “sell” rating in a report on Monday, October 16th. Zacks Investment Research upgraded shares of Zafgen from a “hold” rating to a “buy” rating and set a $4.25 price target on the stock in a report on Saturday, November 11th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. Zafgen currently has a consensus rating of “Hold” and a consensus price target of $6.63.

In other Zafgen news, Director Frances K. Heller purchased 10,000 shares of the business’s stock in a transaction that occurred on Friday, October 13th. The shares were purchased at an average price of $3.90 per share, for a total transaction of $39,000.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Company insiders own 21.20% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Somewhat Positive Media Coverage Somewhat Unlikely to Impact Zafgen (ZFGN) Share Price” was originally posted by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at

About Zafgen

Zafgen, Inc is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company’s lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including severe obesity in rare diseases, such as Prader-Willi syndrome (PWS) and hypothalamic injury-associated obesity (HIAO), including craniopharyngioma-associated obesity.

Insider Buying and Selling by Quarter for Zafgen (NASDAQ:ZFGN)

Receive News & Ratings for Zafgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zafgen Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.